July 19, 2017
FDA accepts new IND to expand in U.S. IFNalpha kinoid clinical development program in dermatomyositis
The U.S. Food and Drug Administration (FDA) has cleared Neovacs’s Investigational New Drug (IND) application for IFNalpha Kinoid in the treatment of dermatomyositis, which allows the Company to initiate in the US its Phase IIa clinical trial already on-going in European countries.
